Larotrectinib Is Highly Active in Patients With Advanced Recurrent TRK Fusion Thyroid (TC) and Salivary Gland Cancers (SGC)

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

ELSEVIER SCIENCE INC

1. Loxo Oncology
2. Merck
3. Bristol-Myers squibb
4. Astra-Zeneca
5. Ignyta, Inc
6. Novartis
7. Adapitimmune
8. Abbvie
9. Amgen
10. BMS
11. Daiichi-Sanko
12. Eisai
13. Genentech
14. Genmab
15. Ignyta
16. Kite
17. Kyowa
18. Lilly
19. Loxo
20. Bayer
21. Medimmune
22. Mirati
23. Molecular Template
24. Pfizer
25. Takeda